Jun 12, 2019

Congress lukewarm on helping biosimilars

Illustration: Aïda Amer/Axios

Congress isn't feeling much urgency to help the fledgling market for biosimilars.

Why it matters: Advocates say that they need lawmakers' help soon, or else drugmakers will see biosimilars as a lost cause and the system will lose its only check on the cost of biologics.

Where it stands: Congress' ideas to enhance competition among traditional generics wouldn't do much for biosimilars — less than a dozen of which are on the market.

  • “Different things need to be done for biosimilars because it’s a new industry," said Juliana Reed, president of the Biosimilars Forum.
  • Lawmakers "don’t seem to appreciate" how many of the drugs have been stymied by intellectual property challenges or backwards commercial incentives, said Chip Davis, president and CEO of the Association for Accessible Medicines.

What they're saying: Both groups want Congress to alter Medicare's financial incentives to help bolster biosimilars. Davis' group also wants it to speed up patent lawsuits.

The other side: "It’s unclear that anything actually needs to be done on biosimilars as the law is still in its nascent stages," said a senior GOP aide working on drug prices.

Where it stands: The Senate health committee recently proposed accelerating the biosimilar approval process. Sens. John Barrasso and Sherrod Brown also said they'll have bills coming soon.

Yes, but: "I guess the answer ought to be yes. But I don’t know all of the issues yet," Finance Committee Chairman Chuck Grassley said when asked about increasing biosimilar competition.

Go deeper: How cheaper drugs are kept off the market

Go deeper

Italy becomes site of largest coronavirus outbreak outside of Asia

Data: The Center for Systems Science and Engineering at Johns Hopkins, the CDC, and China's Health Ministry. Note: China numbers are for the mainland only and U.S. numbers include repatriated citizens.

The novel coronavirus has spread to more nations as South Korea and Italy step up emergency measures in their countries amid rising case numbers on Sunday.

The big picture: COVID-19 has killed at least 2,462 people and infected almost 79,000 others, mostly in mainland China. South Korea increased the infectious disease alert to red, the highest possible, as its case numbers jumped to 602 and the death toll to five. Italy's government announced emergency measures as it confirmed a spike from three to 132 cases in matter of days, making it the largest outbreak outside of Asia.

Go deeperArrowUpdated 1 hour ago - Health

Iranian state TV: Hardliners win landslide victory in low-turnout election

Photo: Iranian Supreme Leader Press Office/Handout/Anadolu Agency via Getty Images

Iranian state TV announced Sunday that hardliners won a landslide victory in the country's parliamentary elections two days ago, including all 30 seats in Tehran, AP reports.

Why it matters: Voter turnout in the election only reached 42.57%, according to Iran's interior ministry, the first time turnout dipped below 50% since the 1979 Islamic Revolution. The low turnout may signal dissatisfaction with the Iranian government and the election system.

Go deeperArrow1 hour ago - World

Coronavirus threatens shortages of about 150 drugs

A medical worker in Beijing. Photo: Greg Baker/AFP via Getty Images

About 150 prescription drugs — including antibiotics, generics and some branded drugs without alternatives — are at risk of shortage if the coronavirus outbreak in China worsens, according to two sources familiar with a list of at-risk drugs compiled by the Food and Drug Administration.

Why it matters: China is a huge supplier of the ingredients used to make drugs that are sold in the U.S. If the virus decreases China's production capability, Americans who rely on the drugs made from these ingredients could be in trouble.